Encysive Pharmaceuticals — ThinkEquity Partners 4th Annual Growth Conference 2006
25 slides from Encysive Pharmaceuticals's conference presentation, Sep 11, 2006

Slide 1: ThinkEquity Partners 4th Annual Growth Conference
ThinkEquity Partners 4th Annual Growth Conference September 11, 2006

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 3: Overview
Overview Encysive is engaged in the development and commercialization of novel, synthetic, small molecule compounds in the area of vascular biology Company headquarters in Houston; European operations (Encysive UK Ltd) based outside London First product (Argatroban) approved and marketed by GlaxoSmi

Slide 4: Investment Highlights
Investment Highlights In August 2006 THELIN(r) (sitaxentan sodium) 100 mg tablets approved for treatment of PAH in all 25 countries of European Union

Slide 5: Investment Highlights
Investment Highlights 3 additional regulatory reviews pending for THELIN(tm) US FDA "approvable letter" Australia (priority review) Canada Commercial organization in place in both United States and Europe Attractive product opportunity ENCY owns 100% of worldwide THELIN revenues Efficient market, pr

Slide 6: Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) Rare, life-threatening condition causing high blood pressure in the lungs due to narrowing and stiffening of pulmonary arteries Symptoms include shortness of breath, fatigue, dizzy spells, fainting, chest pain, and swelling of ankles and legs PAH may develop wit

Slide 7: PAH - A Growing Market Opportunity
PAH - A Growing Market Opportunity... Estimated 100,000 - 200,000 patients in North America and Europe Market still growing rapidly Physician awareness continues to grow More than $500MM in ETRA product sales in NA and EU in 2005 with double digit growth New entrant can fuel growth Rate of diagnosis

Slide 8: Diagnosed PAH Patients Projected to Double by 2009
Diagnosed PAH Patients Projected to Double by 2009... Source: Encysive Internal Market Model, 2005

Slide 9: Basis for Regulatory Submissions
Basis for Regulatory Submissions Two successful pivotal trials completed (STRIDE-1, STRIDE-2) More than 1,000 PAH patients treated with THELIN(tm) in clinical studies

Slide 10: STRIDE-1: Efficacy
STRIDE-1: Efficacy At 12 weeks, THELIN(tm) 100 mg (vs. placebo) improved: 6MW distance (placebo-corrected 35 m, p < 0.01) WHO FC (29% improved, p < 0.02) Hemodynamics PVR decreased 221 dyn/sec/cm-5 (p < 0.001) CI increased 0.3 L/min/m2 (p < 0.02) TRA06069 04.20.06 Barst RJ, et al. Am J Respir Crit C

Slide 11: STRIDE-2: Efficacy
STRIDE-2: Efficacy Treatment with THELIN(tm) 100 mg (vs. placebo) at 18 weeks: Increased 6MW distance: treatment effect 31.4 m (p= 0.03) Improved WHO functional class: 98% improved or unchanged (p= 0.04) Barst RJ, et al. J Am Coll Cardiol. 2006;47:2049-2056

Slide 12: THELIN Safety and Tolerability
THELIN(tm) Safety and Tolerability Favorable liver function test (LFT) elevations* STRIDE-1 (12 Weeks) 0% for THELIN 100 mg 3% for Placebo STRIDE-2 (18 Weeks) 3% for THELIN 100 mg 6% for Placebo 11% for Tracleer(r) Class effect seen with THELIN, Tracleer and ambrisentan * Single elevation greater th

Slide 13: THELIN Safety and Tolerability
THELIN(tm) Safety and Tolerability Adverse events typical for vasodilators E.g.: Headache, nasal congestion, nausea, edema Well-characterized interaction with warfarin Handled by dose adjustment Warfarin requires close monitoring irrespective of treatment selection Monthly liver and pregnancy* testi

Slide 14: THELIN Approved in the EU
THELIN(r) Approved in the EU Approved in August 2006 for marketing in all 25 EU countries THELIN 100 mg indicated for the treatment of patients with PAH classified as World Health Organization functional class III, to improve exercise capacity. Efficacy has been shown in primary (idiopathic) pulmona

Slide 15: THELIN in EU: A 2nd Generation ETRA with Competitive Advantages
THELIN(r) in EU: A 2nd Generation ETRA with Competitive Advantages Once-daily oral tablet Lower rate of liver function test elevations Efficacy demonstrated in PAH associated with CTD No clinically meaningful interaction with sildenafil Only highly selective ETRA for PAH Only ETRA with comparator da

Slide 16: EU Operations
EU Operations Established European HQ in UK EU operations headed by Thierry Plouvier, M.D. Country managers in place for France, Germany & UK Approximately 35 sales reps. planned for Europe UK sales organization on board and trained Germany recruiting for 4Q launch

Slide 17: EU Sales Roll-Out
EU Sales Roll-Out First launch countries, UK and Germany, targeted for Q4 2006 Additional key countries targeted for 2007 launch Spain France Italy Netherlands

Slide 18: Ready to Launch in the US
Ready to Launch in the US 52 sales representatives trained, ready-to-go Average 11 years pharmaceutical sales experience Initial comments received from FDA on ENCY's plans for its risk map Managed care team in place Top 50 payers targeted

Slide 19: US Regulatory Status
US Regulatory Status Second FDA "approvable letter" for THELIN(tm) received on July 24 ENCY is working diligently with FDA Constructive dialogue (oral, written and face-to-face) We remain hopeful that we can resolve the remaining item without additional clinical work, discussions are ongoing

Slide 20: Pipeline Chart
Pipeline Chart PROPRIETARY PRODUCTS Thelin(tm) Oral Thelin(tm) Oral- US PC1 Oral PC2 Oral PC3 Intravenous PAH Undisclosed ILD Thelin(tm) Oral Undisclosed Undisclosed TBC3711 Oral* Thelin(tm) Intravenous TBC3711 Intravenous* Undisclosed Undisclosed Undisclosed Resistant HTN Undisclosed PARTNERED PROD

Slide 21: Senior Management Team with Significant Global Pharmaceutical Experience
Senior Management Team with Significant Global Pharmaceutical Experience... Bruce Given, M.D. President and CEO Formerly President, International of Ortho - -Clinical Diagnostics a Johnson & Johnson Company George Cole COO Formerly President of Altana Pharma U.S. Richard Dixon, Ph.D. CSO Formerly Di

Slide 22: Summary
Summary 1 product approved, and 1 "approvable" in US 1 product approved in European Union EU product revenues expected to begin in Q4 2006 3 active regulatory filings Commercially ready for US launch Argatroban royalty income continues to grow Additional indications for THELIN(tm) in clinical develo

Slide 23: Second Quarter 2006 Financial Results
Second Quarter 2006 Financial Results $ millions Revenue Net loss $3.7 ($28.0) Cash & investments at June 30, 2006 $75.4

Slide 24: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 25: ThinkEquity Partners 4th Annual Growth Conference
ThinkEquity Partners 4th Annual Growth Conference September 11, 2006
Source: SEC EDGAR · 8-K filed Sep 11, 2006
More decks from Encysive Pharmaceuticals Inc
26th Annual JPMorgan Healthcare Conference 200825 slides · Jan 8, 2008
2007 UBS Global Life Sciences Conference21 slides · Sep 24, 2007
Cowen and Company 27th Annual Health Care Conference 200724 slides · Mar 13, 2007
BIO CEO & Investor Conference 200724 slides · Feb 13, 2007
Rodman & Renshaw Healthcare Conference 200625 slides · Nov 6, 2006
JPMorgan Healthcare Conference 200627 slides · Jan 9, 2006